New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
08:54 EDTHEBHemispherx wins federal lawsuit regarding investment banking fees
Hemispherx Biopharma announced after more than a week in trial, a federal jury in Atlanta took only an hour to determine there was no merit to a brokerage firm's claim that Hemispherx owed the firm over $6M for commissions from private sales of stock in 2009. MidSouth Capital, sued Hemispherx in 2010 for commissions it claimed it was due under the terms of a 2008 contract which Hemispherx never signed. Investment bank Rodman & Renshaw sold more than $31M worth of Hemispherx stock in mid-2009. Rodman & Renshaw was promptly paid the commission it was due under the terms of its engagement agreement. MidSouth, whose brokers, Rob Rosenstein and Adam Cabibi, were terminated after they failed to secure a closing on several failed convertible debenture proposals, also demanded payment of a commission on the subsequent Rodman & Renshaw stock sale.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
09:27 EDTHEBHemispherx says Ampligen blocks certain Ebola Viral Disease protein
Hemispherx Biopharma announced that it had received a new research report from Professor Tramontano in the Department of Life and Environmental Sciences, University of Cagliari, Italy. The biochemical study demonstrates Ampligen can successfully bind to the lethal EVD viral protein designated VP35. Experiments being conducted establish the scientific foundation for Ampligen, an experimental drug, as a potential preventive and early onset therapeutic for Ebola, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use